Dow Jones
37.775,38 +22,07 (+0,06%) Nasdaq
15.601,50 -81,87 (-0,52%) Nikkei 225
37.720,57 -359,13 (-0,94%) EUR/USD
1,0639 -0,0007 (-0,06%) Bitcoin EUR
59.237,86 +1.872,27 (+3,26%) CMC Crypto 200
1.308,75 +423,22 (+47,77%)
Chimerix, Inc. (CMRX)
Dopo ore:
| Chiusura precedente | 0,9040 |
| Aperto | 0,9100 |
| Denaro | 0,8949 x 200 |
| Lettera | 0,9602 x 200 |
| Min-Max giorno | 0,8921 - 0,9400 |
| Intervallo di 52 settimane | 0,8800 - 1,5700 |
| Volume | |
| Media Volume | 423.588 |
| Capitalizzazione | 83,171M |
| Beta (5 anni mensile) | 1,10 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,9300 |
| Prossima data utili | 02 mag 2024 - 06 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireChimerix to Participate in Upcoming Investor Conferences
DURHAM, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that management will participate in two upcoming investor conferences: H.C. Wainwright 25th Annual Global Investment Conference in New York City. Mike Andriole, Chief Executive Officer, will present a corporate overview on September 12, 2023 at 9:00 a.m. ET. A l
- GlobeNewswire
Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to ONC201 Treatment of H3 K27M-Mutant Diffuse Midline Gliomas Published in "Cancer Discovery"
Patients Treated with ONC201 Demonstrated Median Overall Survival (mOS) of 21.7 Months in the Front-Line Setting, Post Radiation, Versus 12 Months mOS Historical Control ONC201 Treatment Disrupts Key Metabolic and Epigenetic Pathways DURHAM, N.C., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced the publication of data in
- GlobeNewswire
Chimerix Reports Second Quarter 2023 Financial Results and Provides Operational Update
– Phase 3 ACTION Study Ongoing with 77 Sites Activated Across 11 Countries; Reiterate First Interim Overall Survival Analysis Expected Early 2025 – – ONC206 Dose Escalation Completion Expected in First Half 2024 – – Capital Available to Fund Operations is $233 Million as of June 30, 2023 – – Conference Call at 8:30 a.m. ET Today – DURHAM, N.C., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve
